 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...5152535455565758596061...235236» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) (Available On Demand; Poster Bd # 325b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3145;
P3
bCohort 3 to begin after phase 3 enrollment is complete. cBy BICR.BICR, blinded independent central review; CAPOX, capecitabine/oxaliplatin; FOLFIRI, fluorouracil/leucovorin/irinotecan; FOLFOX, fluorouracil/leucovorin/oxaliplatin; FOLFOXIRI, fluorouracil/leucovorin/oxaliplatin/irinotecan.
- 5-fluorouracil / Generic mfg.
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). (On Demand | Hall A; Poster Bd # 324b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3143;
P2/3
Support: U10CA180868, -180822; UG1CA189867; GuardantHealth. Clinical trial information: NCT04068103.
- AiTan (rivoceranib) / HLB Bio Group
Efficacy and safety of mFOLFOX6 with apatinib as postoperative adjuvant chemotherapy in stage IIIB or IIIC colorectal cancer. (On Demand | Hall A; Poster Bd # 313) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3131;
P3
The toxicities associated with apatinib were generally acceptable. Clinical trial information: NCT03365765.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A secondary endpoint analysis of the ERMES study. (On Demand | Hall A; Poster Bd # 303) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3121;
P3
These data support the hypothesis that ETS might be a clinical dynamic predictor of efficacy of a less intensive maintenance strategy, allowing to plan de-escalation to cet alone after 4 months of FOLFIRI+cet induction. Clinical trial information: NCT02484833.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO). (On Demand | Hall A; Poster Bd # 290) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3108;
P2
The median PFS appears higher compared to historical controls (FOLFIRI/VEGFi). Neutropenia is common and can affect dose density/intensity mandating use of G-CSF.
- Avastin (bevacizumab) / Roche
Optimal molecular-targeted therapies as first-line treatment for RAS (Available On Demand; Poster Bd # 288) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3106;
For patients with RAS wt or RAS/BRAF wt, right-sided mCRC, bevacizumab combination therapy is preferred first-line treatment. >
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials. (Available On Demand; Poster Bd # 278) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3096;
Our results highlight an important role for MHC SNPs as prognostic and predictive biomarkers for first-line treatment in mCRC, with differential effects based on biologic agent and chemotherapy backbone. These biomarkers, when further validated, may contribute to personalized treatment strategies for mCRC patients.
- Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC). (Available On Demand; Poster Bd # 276) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3094;
P2
In MSS mCRC, LOH-high was associated with biallelic alterations in the HRR system, worse prognosis and higher benefit from the addition of anti-PDL1 agents to chemotherapy. Considering the low number of LOH-high tumors in our study, these results deserve confirmation in larger cohorts.
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO. (On Demand | Hall A; Poster Bd # 275) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3093;
P2
Translational analyses to evaluate the impact of immune-related biomarkers are ongoing. Clinical trial information: NCT04513951.
- Avastin (bevacizumab) / Roche
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC). (On Demand | Hall A; Poster Bd # 274) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3092;
The benefit to Triplet/Bev observed in randomized trials does not translate well to a more heterogeneous, real-world population. Sub-group analyses including by age, tumor sidedness, KRAS/NRAS/BRAF status, and baseline CEA level will be performed.
- Vectibix (panitumumab) / Amgen, Takeda
Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study. (On Demand | Hall A; Poster Bd # 271) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3090;
P2
Preliminary data on Acq-GAs suggest that classical mutations associated with anti-EGFR resistance are infrequent with up-front use of anti-EGFR/chemotherapy. Clinical trial information: NCT04425239.
- Avastin (bevacizumab) / Roche
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study. (On Demand | Hall A; Poster Bd # 265) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3084;
P2
Although CAPOXIRI + Bev was associated with increased incidences of certain nonhematologic AEs, it was well tolerated, with a decreased incidence of neutropenia and no unexpected safety signal. Good survival and response results suggest that CAPOXIRI + Bev could become a new first-line treatment option in pts with mCRC.
- Avastin (bevacizumab) / Roche
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial. (On Demand | Hall A; Poster Bd # 264) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3083;
P=N/A
Good survival and response results suggest that CAPOXIRI + Bev could become a new first-line treatment option in pts with mCRC. The SIRFLOX trial investigated the efficacy and safety of adding radioembolization using yttrium-90 resin microspheres (SIRT) to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)
- Vectibix (panitumumab) / Amgen, Takeda
Size-related heterogeneity of colorectal liver metastases (CRLM) in patients with advanced RAS wild-type metastatic colorectal cancer (mCRC) treated in the PanaMa trial: Implication for treatment decisions. (On Demand | Hall A; Poster Bd # 253) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3072;
P2
In addition, the efficacy of Pmab during maintenance was evident in both patient groups (homogeneous and heterogeneous disease lesions) with a numerically greater effect in patients with heterogeneous lesions. Clinical trial information: NCT01991873.
- Opdivo (nivolumab) / Ono Pharma, BMS
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial. (On Demand | Hall A; Poster Bd # 252) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3071;
P2
With equal primary endpoint for the ITT cases, alternating short-course oxaliplatin-based therapy and nivolumab significantly improved PFS compared to standard first-line chemotherapy in MSS-CRC patients ?60 years with abdominal metastases. Clinical trial information: NCT03388190.
- Vectibix (panitumumab) / Amgen, Takeda
Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212). (On Demand | Hall A; Poster Bd # 251) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3070;
P2
Additionally, number and largest size of CRMs proofed predictive of PFS of maintenance therapy with Pmab, the primary endpoint of the trial. Patients with high metastatic burden at baseline appear to benefit particularly from Pmab-containing maintenance therapy.
- Avastin (bevacizumab) / Roche
A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study. (On Demand | Hall A; Poster Bd # 249) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3068;
This regimen maybe a useful as second-line treatment option in such patients. Clinical trial information: jRCTs071190003.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study). (On Demand | Hall A; Poster Bd # 244) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3065;
These preliminary data suggest a possible prognostic role of TP53 variants in RAS/BRAF wild type mCRC patients receiving first line FOLFIRI/cetuximab followed by Cet alone. Comprehensive genomic profiling is ongoing to identify genomic signatures associated with sensitivity to Cet.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Artificial intelligence (On Demand | Hall A; Poster Bd # 242) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3063;
P3
A data-driven immune-desert phenotype was identified in dMMR tumors that was associated with significantly poorer survival. Further investigation of the potential predictive utility of these phenotypes for immunotherapy are planned.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study. (Available On Demand; Poster Bd # 234) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3055;
P2
Our results prompt the design of microbiota-centered diagnostic tests to identify pMMR mCRC patients more likely to benefit from ICI-based therapeutic strategies. Clinical trial information: NCT03721653.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas. (On Demand | Hall A; Poster Bd # 227) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3048;
P3
Among pMMR tumors, tumor budding/poorly differentiated clusters was the strongest predictor of DFS. Support: NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS).
- Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients. (On Demand | Hall A; Poster Bd # 226) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3047;
We describe an association between FOLFOX and subsequent infiltration by CD8+ T-cells and high PDL1+ rates in R-CRC, BRAF-mut CRC, and FOLFIRI-treated L-CRC. The findings provide insights for future therapeutic strategies.
- Vectibix (panitumumab) / Amgen, Takeda
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3043;
P3
Clinical trial information: NCT02394795. >
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3042;
P3
These patients show outcome characteristics expected for RAS mutant patients (median PFS of 9.0 months and median OS of 22 months). The study thus shows the clinical relevance of liquid biopsy in the verification of RAS mutational status.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3039;
P2/3
Comparing with fluorouracil plus radiation, mFOLFOX6 plus radiation also failed to improve long-term survival. Clinical trial information: NCT01211210.
- irinotecan / Generic mfg.
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3038;
P3
NACT with mFOLFIRINOX followed by CRT, surgery, and ACT significantly improved all outcomes, including OS in pts with LARC vs those who received standard CRT, surgery, and ACT. Clinical trial information: NCT01804790.
- 5-fluorouracil / Generic mfg.
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. (Live Stream | Hall D2) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3037;
P3
However, neoadjuvant chemotherapy seemed to have more favorable outcomes in terms of chemotherapy cycles, postoperative complications, and downstaging. CT scan alone may not be sufficient in identifying high-risk patients preoperatively.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study. (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3034;
P2
These findings deserve confirmation in a properly designed phase III trial. Clinical trial information: NCT03721653.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
A pragmatic, single-arm clinical trial of a dose-adjustment algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy. (On Demand | Hall A; Poster Bd # 100) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2707;
P=N/A
The incidence of any cytopenia-related delay was 15%, lower than the historical rate of >30%. Further refinement and evaluation of the FOLFOX dose adjustment algorithm may help to reduce unplanned delays and their attendant disruptions and costs for patients and providers.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study. (On Demand | Hall A; Poster Bd # 244) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1747;
These preliminary data suggest that liquid biopsy might better recapitulate the heterogeneity of mCRC and might be useful in clinical practice to complement tissue testing. The clinical relevance of RAS variants detected in cfDNA will be determined in the LIBImAb trial.
- A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity. (On Demand | Hall A; Poster Bd # 226) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1730;
Clinical implementation of testing for this variant has the potential to identify almost half of those at risk of FP-induced cardiovascular toxicity with high specificity, thereby enabling changes to their clinical management. >XELOX: Oxaliplatin and Capecitabine; OxMDG/FOLFOX: leucovorin, 5-FU, oxaliplatin; CMF: cyclophosphamide, methotrexate, 5-FU.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial. (Live Stream | Hall D2; Poster Bd # 344) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1344;
P3
Neoadjuvant HAIC with FOLFOX regimen before hepatectomy may bring survival benefits for resectable BCLC stage A/B HCC patients beyond Milan criteria. Clinical trial information: NCT03851913.
- albumin-bound paclitaxel / Generic mfg.
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-na (Live Stream | Hall D2; Poster Bd # 342) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1342;
P2
In view of the published evidence, the present data supports the hypothesis that sequential NAPOLI/mFOLFOX6 may be equally effective with regard to OS, but less toxic, compared to mFOLFIRINOX. Clinical trial information: NCT03487016.
- Baizean (tislelizumab) / BeiGene, Novartis, sirexatamab (DKN-01) / Leap Therap
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). (Live Stream | Hall D2; Poster Bd # 335) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1332;
P2
The prolonged PFS and OS observed in the current study are notable, especially in our trial population dominated by patients with tumors of low PD-L1 expression, where the known benefit of anti-PD-1 therapy is limited. The ongoing Part C of this study is evaluating mFOLFOX6/CAPOX plus tislelizumab with or without DKN-01 in the same 1L GEA patient population.
- zimberelimab (AB122) / Arcus Biosci, Otsuka, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead, Otsuka, Opdivo (nivolumab) / Ono Pharma, BMS
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. (On Demand | Hall A; Poster Bd # 509b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1330;
P3
STAR-221 is currently enrolling globally. Clinical trial information: NCT05568095.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. (On Demand | Hall A; Poster Bd # 508b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1328;
P3
All patients enrolled undergo central radiologic eligibility review for quality control and are then randomized to either Arm 1 which consists of 8 cycles of neoadjuvant mFOLFIRINOX followed by 4 cycles of adjuvant mFOLFIRINOX or Arm 2 which includes upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX...The Alliance A021806 phase III trial aims to define a new standard of care for patients with resectable pancreatic cancer. Clinical trial information: NCT04340141.
- Keytruda (pembrolizumab) / Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001. (On Demand | Hall A; Poster Bd # 505b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1322;
P2
Key eligibility criteria include: mPDA pts with gBRCA1/2 pathogenic variants identified with standard of care germline genetic testing and progression-free after receiving at least 16 weeks of platinum-based chemotherapy (FOLFIRINOX, FOLFOX or gemcitabine/cisplatin +/- nab-paclitaxel)...Prospective serial blood samples will be collected to bank DNA and RNA for future correlative studies. Clinical trial information: NCT04548752.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC). (Available On Demand; Poster Bd # 503a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1317;
P2
This is the first clinical study to prospectively evaluate the value of multimodality therapy concepts in oligometastatic pancreatic cancer. Clinical trial information: NCT04617457.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study. (Available On Demand; Poster Bd # 501b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1314;
P2
Clinical trial information: NCT03483038. >
- vudalimab (XmAb717) / Xencor
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers. (Available On Demand; Poster Bd # 498b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1308;
P2
> More recently, TOPAZ-1 demonstrated a modest, but significant overall survival benefit (HR 0.80; 95% CI 0.66
- Tecentriq (atezolizumab) / Roche
A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK. (Available On Demand; Poster Bd # 495a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1302;
P2
More recently, TOPAZ-1 demonstrated a modest, but significant overall survival benefit (HR 0.80; 95% CI 0.66 Pts are randomized 1:1 to 4 pre-operative 2-week cycles (8 weeks) of FLOT (Docetaxel 50 mg/m
- Opdivo (nivolumab) / Ono Pharma, BMS, osemitamab (TST001) / Transcenta
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101. (Available On Demand; Poster Bd # 494b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1301;
P1/2
Data from this trial will support the selection of the optimal dose and dose regimen of TST001 in these combinations. Enrollment in the trial is ongoing.
- Opdivo (nivolumab) / Ono Pharma, BMS
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA). (Available On Demand; Poster Bd # 494a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1300;
P3
This study is a randomized phase III, open-label, multicenter clinical trial with the primary objective to determine whether modified FOLFIRINOX (FU 2400 mg/m2, leucovorin 400 mg/m2, oxaliplatin 85 mg/m2, irinotecan 150 mg/m2 every 2 weeks) as first-line treatment improves OS compared to mFOLFOX in patients with advanced HER2 negative GEA...The study accrual began January 2023. Clinical trial information: NCT05677490.
- zolbetuximab (IMAB362) / Astellas, Opdivo (nivolumab) / Ono Pharma, BMS
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. (Available On Demand; Poster Bd # 493a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1298;
P2
Currently, 20+ sites are recruiting in 6 countries (France, Italy, Japan, Korea, Taiwan, United States); more US sites are planned. Clinical trial information: NCT03505320.
- Keytruda (pembrolizumab) / Merck (MSD)
A phase 2 trial of chemotherapy, pembrolizumab, and propranolol in patients with advanced esophageal/gastroesophageal junction adenocarcinoma (EGAC). (Available On Demand; Poster Bd # 492a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1296;
P2
Eligible patients will receive mFOLFOX6 every two weeks in combination with pembrolizumab 400 mg intravenously every six weeks and propranolol 30 mg orally twice daily...The study is currently open to enrollment. Clinical trial information: NCT05651594.
- Imfinzi (durvalumab) / AstraZeneca
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer. (Available On Demand; Poster Bd # 485) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1289;
P1/2
Immuno-genomic biospecimen analyses underway. Clinical trial information: NCT03245541.
- Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC). (Available On Demand; Poster Bd # 472) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1277;
Our data show a strong association between tumor DSCR1 gene expression, several pathway alterations, immune-related gene expression, TME cell infiltration and patient survival. These findings suggest DSCR1 as a candidate prognostic biomarker and as a potential treatment target in PDAC.
- 5-fluorouracil / Generic mfg.
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen. (Available On Demand; Poster Bd # 471) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1276;
The opposite trend was seen in patients with other KRAS variants including G12D, G12V, and G12R, consistent with the recently presented NAPOLI-3 trial. PDL1 staining was also highest in the KRAS G12C cohort.
- Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC). (Available On Demand; Poster Bd # 470) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1275;
Using RWE, the PDACai signature successfully predicted relative differences in PFS on both FFX and GA in mPDAC. With prospective validation, personalized insights generated by PDACai from pts with similar biomarker profiles could be used to tailor treatment sequencing in pts with NGS testing results, particularly those without actionable genomic findings.
- Clinical genomic implications of transcriptional subtypes in pancreatic cancer. (Available On Demand; Poster Bd # 466) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1271;
Our work represents the largest known real world molecular comparison of transcriptional subtypes of PC. Differential outcomes for patients with basal tumors treated with FFX versus GnP warrants further investigation in prospective studies.